These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10917417)

  • 1. Tranylcypromine plus risperidone for treatment-refractory major depression.
    Stoll AL; Haura G
    J Clin Psychopharmacol; 2000 Aug; 20(4):495-6. PubMed ID: 10917417
    [No Abstract]   [Full Text] [Related]  

  • 2. Risperidone plus a monoamine oxidase inhibitor for agitated depression crisis.
    Welner M
    J Clin Psychopharmacol; 1996 Dec; 16(6):460-1. PubMed ID: 8959474
    [No Abstract]   [Full Text] [Related]  

  • 3. Bupropion-tranylcypromine combination for treatment-refractory depression.
    Pierre JM; Gitlin MJ
    J Clin Psychiatry; 2000 Jun; 61(6):450-1. PubMed ID: 10901349
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate.
    Nolen WA; van den Broek WW; Birkenhäger TK
    Am J Psychiatry; 2007 Mar; 164(3):524; author reply 524. PubMed ID: 17329480
    [No Abstract]   [Full Text] [Related]  

  • 5. Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
    Goforth HW; Carroll BT
    J Clin Psychopharmacol; 2007 Apr; 27(2):216-7. PubMed ID: 17414252
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants.
    Nolen WA; Haffmans PM; Bouvy PF; Duivenvoorden HJ
    J Affect Disord; 1993 Jul; 28(3):189-97. PubMed ID: 8408980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tranylcypromine treatment of major depression.
    Liebowitz MR
    J Clin Psychiatry; 1987 Jul; 48(7):303. PubMed ID: 3597337
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients.
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    J Clin Psychiatry; 2004 Nov; 65(11):1505-10. PubMed ID: 15554763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine.
    Volz HP; Faltus F; Magyar I; Möller HJ
    J Affect Disord; 1994 Mar; 30(3):209-17. PubMed ID: 8006247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine Oxidase Inhibition in a Patient With Type 1 Diabetes and Depression.
    Emory H; Mizrahi N
    J Diabetes Sci Technol; 2016 Sep; 10(5):1203-4. PubMed ID: 26961977
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute exacerbation of depression after discontinuation of monoamine oxidase inhibitor prior to cardiac surgery.
    Abdi S; Fishman SM; Messner E
    Anesth Analg; 1996 Sep; 83(3):656-7. PubMed ID: 8780301
    [No Abstract]   [Full Text] [Related]  

  • 12. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase inhibitors as treatment for depressed patients with primary degenerative dementia (Alzheimer's disease).
    Jenike MA
    Am J Psychiatry; 1985 Jun; 142(6):763-4. PubMed ID: 4003602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAO inhibition as antidepressive mechanism reevaluated. A controlled study with tranylcypromine isomers.
    Beckmann H; Moises HW
    Mod Probl Pharmacopsychiatry; 1983; 19():211-4. PubMed ID: 6865965
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brofaromine in non-endogenous major depressed inpatients--results of a preliminary dose-finding trial versus tranylcypromine.
    Volz HP; Heimann H; Bellaire J; Laux G; Möller HJ
    Pharmacopsychiatry; 1994 Jul; 27(4):152-8. PubMed ID: 7972347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoamine oxidase inhibitors in the treatment of obsessive disorders. Two case reports and review of the literature].
    Erfurth A; Schmauss M
    Nervenarzt; 1993 Jan; 64(1):70-2. PubMed ID: 8437650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on STAR*D: a summary and UK perspective.
    Cowen PJ
    J Psychopharmacol; 2009 Aug; 23(6):618-9; discussion 622-4. PubMed ID: 19395431
    [No Abstract]   [Full Text] [Related]  

  • 19. Tranylcypromine isomers in depressed outpatients: effects on depression, monoamine oxidase inhibition and tyramine pressor response.
    Van de Merwe TJ; Pare CM; Glover V; Sandler M
    Mod Probl Pharmacopsychiatry; 1983; 19():189-202. PubMed ID: 6346066
    [No Abstract]   [Full Text] [Related]  

  • 20. Do antihypertensives make tranylcypromine safer? Three case reports.
    Taylor BP; Quitkin FM; McGrath PJ; Stewart JW
    J Clin Psychiatry; 2005 May; 66(5):657-8. PubMed ID: 15889959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.